OMass Therapeutics Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
75
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$310M
- Investors
-
13
OMass Therapeutics General Information
Description
Developer of a structural mass spectrometry technology platform designed to help clients discover medicines. The company's platform offers access to native mass spectrometry without having to establish sophisticated instrumentation and expertise in-house, and provides a way to study complex protein assemblies and their interactions with other biological molecules, enabling biotechnology and pharmaceutical clients to tackle challenging drug targets and biotherapeutics within a collaborative framework.
Contact Information
Website
www.omass.comCorporate Office
- Building 4000, Chancellor Court
- John Smith Drive, ARC Oxford
- Oxford OX4 2GX
- England, United Kingdom
Corporate Office
- Building 4000, Chancellor Court
- John Smith Drive, ARC Oxford
- Oxford OX4 2GX
- England, United Kingdom
OMass Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC (Series C) | 15-Oct-2026 | $310M | Completed | Clinical Trials - Phase 1 | ||
| 7. Secondary Transaction - Private | Completed | Clinical Trials - Phase 1 | ||||
| 6. Later Stage VC (Series B) | 19-Apr-2022 | Completed | Clinical Trials - Phase 1 | |||
| 5. Early Stage VC (Series A) | 13-Feb-2020 | Completed | Clinical Trials - Phase 1 | |||
| 4. Early Stage VC (Series A) | 26-Jun-2018 | Completed | Clinical Trials - Phase 1 | |||
| 3. Grant | 01-Mar-2018 | Completed | Clinical Trials - Phase 1 | |||
| 2. Seed Round | 29-Mar-2016 | $3.07M | $3.07M | Completed | Pre-Clinical Trials | |
| 1. University Spin-Out | 26-Feb-2016 | Completed | Pre-Clinical Trials |
OMass Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| B Ordinary | ||||||||
| Series A | ||||||||
| A Ordinary | 6,153,846 | $0.001311 | $1.7 | $1.7 | 1x | $1.7 | 6.85% | |
| Ordinary | 1,165,513 | $0.001311 | $1.31 | $1.31 | 1x | $1.31 | 1.3% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
OMass Therapeutics Comparisons
Industry
Financing
Details
OMass Therapeutics Competitors (28)
One of OMass Therapeutics’s 28 competitors is Ambrx, a Formerly PE-Backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ambrx | Formerly PE-Backed | San Diego, CA | ||||
| Selecta Biosciences | Formerly VC-backed | Watertown, MA | ||||
| Relay Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Amunix Pharmaceuticals | Formerly PE-Backed | South San Francisco, CA | ||||
| United Biomedical | Venture Capital-Backed | Dallas, TX |
OMass Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
OMass Therapeutics Patents
OMass Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202510603-D0 | Pharmaceutical compounds | Pending | 01-Jul-2025 | ||
| GB-202502686-D0 | Pharmaceutical compounds | Inactive | 25-Feb-2025 | ||
| GB-202414834-D0 | Pharmaceutical compounds | Inactive | 09-Oct-2024 | ||
| GB-202414836-D0 | Pharmaceutical compounds | Inactive | 09-Oct-2024 | ||
| GB-202414093-D0 | Mc2r modulator compounds | Inactive | 25-Sep-2024 |
OMass Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
OMass Therapeutics Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bain Capital Life Sciences | Corporate Venture Capital | Minority | ||
| Forbion | Venture Capital | Minority | ||
| Janus Henderson Investors | Asset Manager | Minority | ||
| Jefferson Life Sciences | Venture Capital | Minority | ||
| Novo Holdings | Venture Capital | Minority |
OMass Therapeutics Acquisitions (1)
OMass Therapeutics’s most recent deal was a Merger/Acquisition with Excellerate Bioscience (Pharmacology Capabilities Business Unit). The deal was made on 25-Feb-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Excellerate Bioscience (Pharmacology Capabilities Business Unit) | 25-Feb-2020 | Merger/Acquisition | Biotechnology |
OMass Therapeutics FAQs
-
When was OMass Therapeutics founded?
OMass Therapeutics was founded in 2016.
-
Where is OMass Therapeutics headquartered?
OMass Therapeutics is headquartered in Oxford, United Kingdom.
-
What is the size of OMass Therapeutics?
OMass Therapeutics has 75 total employees.
-
What industry is OMass Therapeutics in?
OMass Therapeutics’s primary industry is Drug Discovery.
-
Is OMass Therapeutics a private or public company?
OMass Therapeutics is a Private company.
-
What is OMass Therapeutics’s current revenue?
The current revenue for OMass Therapeutics is .
-
How much funding has OMass Therapeutics raised over time?
OMass Therapeutics has raised $481M.
-
Who are OMass Therapeutics’s investors?
Bain Capital Life Sciences, Forbion, Janus Henderson Investors, Jefferson Life Sciences, and Novo Holdings are 5 of 13 investors who have invested in OMass Therapeutics.
-
Who are OMass Therapeutics’s competitors?
Ambrx, Selecta Biosciences, Relay Therapeutics, Amunix Pharmaceuticals, and United Biomedical are some of the 28 competitors of OMass Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
